Pharmaceutical News

RSS

Global weight management ingredients market to reach $13.9 million by 2015

Obesity rates, which have been steadily rising in Europe and the United States, are now increasing in Asian nations as well. While healthy eating and lifestyle management are the key solutions to weight management, they remain challenging for many consumers. As a result, the weight management ingredients market offers significant prospects worldwide.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

PBMs: Post Office plan to end Saturday shipments could boost drug prices

Pharmacy-benefits management companies, including CVS Caremark and Medco, are worried that a U.S. Postal Service plan to end Saturday delivery could raise mail-order drug prices, Bloomberg Businessweek reports. "The pharmacy-benefits management companies, which shipped more than 150 million drug orders last year, joined retailer Crate and Barrel and publishers of small newspapers to challenge the Postal Service and its plan to cut service to save about $3 billion a year." The Post Office is trying to combat a projected $7 billion deficit this year (Keane, 6/21).

23 Jun 2010

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

GlaxoSmithKline and Medivir today announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets. Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Walmart and Eli Lilly and Company announced today they're teaming up to provide an affordable insulin option for people with diabetes.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

FDA approves Hospira's meropenem for injection, USP (I.V.)

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were approximately $200 million in 2009.

23 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

PharmaTrust to introduce MedCentre remote pharmacy dispensing machine in UK

PharmaTrust will become the first company to introduce a remote pharmacy dispensing machine into the UK later this year. The Oakville, Ontario-based company announced yesterday at an event at Grocer's Hall in London that it is commencing trials of its MedCentre dispensing technology at five hospitals in the UK. Guests included government representatives, pharmacy stakeholders and media.

22 Jun 2010

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Ricerca Biosciences, a uniquely integrated preclinical contract research drug development company providing services to the pharmaceutical industry, is pleased to announce that its Ricerca France, Lyon facility, has recently obtained the ISO 9001:2008 certification for all activities performed at the site.

22 Jun 2010

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID. At the conference, the Company reviewed positive data from an open label Phase II mantle cell lymphoma clinical trial and reported plans to meet with the FDA later this year to discuss a pathway to seek regulatory approval for this hematological indication for which there is no current consensus standard-of-care.

22 Jun 2010

Pharmaceutical News

Global weight management ingredients market to reach $13.9 million by 2015

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

PBMs: Post Office plan to end Saturday shipments could boost drug prices

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

European drugmakers lead in making medicines available to developing world, Index says

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

TheraQuest launches new analgesic product pipeline

Survey: MegaRed Omega-3 Krill Oil recommended for overall cardiovascular health

Exercise alone without creatine supplements helps in cardiac rehabilitation

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

FDA approves Hospira's meropenem for injection, USP (I.V.)

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

PharmaTrust to introduce MedCentre remote pharmacy dispensing machine in UK

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Data on Qnexa to be featured in six presentations at ADA annual meeting

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News